Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
3.440
+0.060 (1.78%)
At close: Oct 15, 2025, 4:00 PM EDT
3.438
-0.002 (-0.07%)
After-hours: Oct 15, 2025, 7:18 PM EDT
CPIX Revenue
Cumberland Pharmaceuticals had revenue of $10.84M in the quarter ending June 30, 2025, with 10.04% growth. This brings the company's revenue in the last twelve months to $42.07M, up 11.34% year-over-year. In the year 2024, Cumberland Pharmaceuticals had annual revenue of $37.87M, down -4.26%.
Revenue (ttm)
$42.07M
Revenue Growth
+11.34%
P/S Ratio
1.18
Revenue / Employee
$462,328
Employees
91
Market Cap
51.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.87M | -1.68M | -4.26% |
| Dec 31, 2023 | 39.55M | -2.46M | -5.85% |
| Dec 31, 2022 | 42.01M | 6.03M | 16.75% |
| Dec 31, 2021 | 35.99M | -1.46M | -3.89% |
| Dec 31, 2020 | 37.44M | 3.05M | 8.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CPIX News
- 2 days ago - CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. - PRNewsWire
- 14 days ago - CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO - PRNewsWire
- 16 days ago - TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA - PRNewsWire
- 2 months ago - Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date - PRNewsWire
- 2 months ago - CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK - PRNewsWire
- 2 months ago - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE - PRNewsWire
- 4 months ago - Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference - PRNewsWire